Enter your terms above and click the 'Search' button.

Showing articles 0 to 15 of 15 Filter Applied: immunomodulation (Click to remove) Acute Encephalitis in Immunocompetent Adults Lancet 393:702-716, Venkatesan, A.,et al, 2019 Clinical Reasoning: A 49-year-old man with Progressive Numbness, Weakness, and Evidence of Leptomeningeal Enhancement Neurol 90:e90-e93, Lovett, A.,et al, 2018 Drug Reaction with Eosinophilia and Systemic Symptoms after Daclizamub Therapy Neurol 91:e359-e363, Rauer,S.,et al, 2018 Morvan Syndrome as a Paraneoplastic Disorder of Thymoma with Anti-CASPR2 antibodies Lancet 389:1367-1368, Vale, T.C.,et al, 2017 Alemtuzumab CARE-MS I 5-year follow-up Neurol 89:1107-1116, Havrdova, E.,et al, 2017 Alemtuzumab CARE-MS II 5-year follow-up Neurol 89:1117-1126, Coles, A.J.,et al, 2017 An 82-year-old man with Worsening Gait Neurol 89:e246-e252, Chew, S.,et al, 2017 Inflammatory Muscle Diseases NEJM 372:1734-1747, Dalakas, M.C., 2015 Effect of high-dose Simvastatin on Brain Atrophy and Disability in Secondary Progressive Multiple Sclerosis (MS-STAT): A Randomised, Placebo-Controlled, Phase 2 Trial Lancet 383:2213-2221, Chataway, J.,et al, 2014 Neurological Immune-Related Adverse Events of Ipilimumab Pract Neurol 13:278-280, Bot, I.,et al, 2013 Autoimmune Epilepsy Arch Neurol 69:582-593,565, Quek, A.M.L.,et al, 2012 Atypical manifestations and poor outcome of herpes simplex encephalitis in the immunocompromised Neurol 79:2125-2132, Tan, L.,et al, 2012 Mechanisms of Fingolimods Efficacy and Adverse Effects in Multiple Sclerosis Ann Neurol 69:759-777, Cohen, J.A. & Chun, J., 2011 Evaluation and Treatment of Inflammatory Myopathies JNNP 80:1060-1068, Amato,A. &Barohn,R.J., 2009 Monoclonal Antibody Therapies and Neurologic Disorders Arch Neurol 65:1162-1165, Novack,J.C.,et al., 2008 Showing articles 0 to 15 of 15